Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses

Thrombosis and Haemostasis

Volumn 85, Issue 5, 2001, Pages 800-805

  Sanmarco, M ^a   Alessi, M C ^a   Harle, J R ^a   Sapin, C ^a   Aillaud, M F ^a   Gentile, S ^a   Juhan Vague, I ^a   Weiller, P J ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Antiphosphatidylethanolamine antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; AUTOIMMUNE DISEASE; BLOOD ANALYSIS; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; FEMALE; FOLLOW UP; GENETIC DISORDER; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA; THROMBOSIS; VEIN THROMBOSIS;

EID: 0035002955     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615751     Document Type: Article

References (29)

1. Clinical and serological features of the "antiphospholipid syndrome"
2. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulant and other "antiphospholipid" autoantibodies
3. Phospholipid binding plasma proteins required for antiphospholipid antibody detection-An overview
4. 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays
5. Use of various methods for anticardiolipin detection in the updated American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
6. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis
7. Evaluation of the clinical and laboratory associations of antiphosphatidylethanolamine antibodies
8. Antibodies to phosphatidylethanolamine in antiphospholipid syndrome and systemic lupus erythematosus: Their correlation with anticardiolipin antibodies and β2-glycoprotein plasma levels
9. Antiphosphatidylethanolamine antibodies in systemic lupus erythematosus
10. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases
11. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early fœtal loss
12. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses
13. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
14. 2-glycoprotein I antibodies in antiphospholipid syndrome: A comparative study with anticardiolipin antibodies
15. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy
16. Comparison of the standardized procedure with current laboratory practices for the detection of lupus anticoagulant in France
17. Antiphosphatidylethanolamine antibodies as a marker for the antiphospholipid syndrome
18. Hepatitis C virus infection and autoimmunity
19. Anticardiolipin antibodies and acquired immunodeficiency syndrome: Prognostic marker or association with HIV infection?
20. Influence of the phosphatidylethanolamine (PE) and bovine serum origins on anti-PE antibody detection by ELISA
21. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex
22. Phosphatidylethanolamine induces specific conformational changes in the Kininogens recognizable by antiphosphatidylethanolamine antibodies
23. Superficial thrombophlebitis and deep vein thrombosis. A controversial association
24. Superficial thrombophlebitis. II. Secondary hypercoagulable states
25. Towards improved criteria for the antiphospholipid syndrome
26. Neurological manifestations of antiphospholipid antibody syndrome
27. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies
28. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells
29. The effect on membrane composition on the hemostatic balance